· ISIN: CA17253X1050

Cipher Pharmaceuticals Reports Second Quarter 2025 Results, Including Record Revenue

(All figures are presented in U.S. Dollars) Highest single-quarter revenue in the Company's history with total revenue of $13.4 million in Q2 2025Adjusted EBITDA1 in Q2 2025 was $7.6 million, an increase of 148% over Q2 2024Epuris sales volumes grew 14% in the quarter compared to Q2 2024NatrobaTM sales were $7.8 million during the quarter, a sequ...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 07.08.2025 | 23:35
07 August 2025 11:35PM
Cipher Pharmaceuticals Reports Second Quarter 2025 Results, Including Record Revenue
(All figures are presented in U.S. Dollars) Highest single-quarter revenue in the Company's history with total revenue of $13.4 million in Q2 2025Adjusted EBITDA1 in Q2 2025 was $7.6 million, an increase of 148% over Q2 2024Epuris sales volumes grew 14% in the quarter compared to Q2 2024NatrobaTM sales were $7.8 million during the quarter, a sequ...
© PR Newswire
29 July 2025 05:28PM
Cipher Pharmaceuticals Schedules Q2 2025 Earnings Release and Conference Call
MISSISSAUGA, ON, July 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The Company will also hold a conference call on Friday, August 8, 2025 at 8:30am ET t...
© PR Newswire
13 June 2025 06:18PM
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, June 13, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular...
© PR Newswire
08 May 2025 11:00PM
Cipher Pharmaceuticals Reports First Quarter 2025 Results, and Announces $15 Million Debt Repayment
(All figures are presented in U.S. Dollars) Adjusted EBITDA2 in Q1 2025 was $6.2 million, an increase of 73% over Q1 2024Canadian product portfolio sales volumes grew 46% in the quarter compared to Q1 2024NatrobaTM sales were $6.7 million during the quarter, a sequential increase of 3% over Q4 2024Continued strong track record of cash generation...
© PR Newswire
02 May 2025 10:05PM
Cipher Pharmaceuticals Schedules Q1 2025 Earnings Release and Conference Call
MISSISSAUGA, ON, May 2, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2025 after the market close on Thursday, May 8, 2025. The Company will also hold a conference call on Friday, May 9, 2025 at 8:30am ET to discuss...
© PR Newswire
01 May 2025 01:00PM
Cipher Pharmaceuticals Announces Normal Course Issuer Bid, Including Intention to Utilize Block Purchases
MISSISSAUGA, ON, May 1, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or "the Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares"). The TSX notice...
© PR Newswire
29 April 2025 01:00PM
Cipher Pharmaceuticals Secures Medicaid Step-Through Preferred Status for Natroba™ in the state of Illinois
MISSISSAUGA, ON, April 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") proudly announces the state of Illinois has updated its Preferred Drug Listing ("PDL") where Cipher's product Natroba™, for the treatment of scabies and head lice, has obtained preferred drug status on Medicaid state plans, an...
© PR Newswire
18 March 2025 10:30PM
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results
(All figures are presented in U.S. Dollars) Generated $8.3 million in cash during Q4 2024Natroba™ revenue was $12.0 million for the 5 months of fiscal 2024 since acquisitionFull year adjusted EBITDA1 of $15.7 million, an increase of 23% over fiscal 2023Cash at December 31, 2024 was $17.8 million or $0.70 per outstanding common shareEpuris revenue...
© PR Newswire
11 March 2025 10:00PM
Cipher Pharmaceuticals Schedules Q4 & Fiscal 2024 Earnings Release and Conference Call
MISSISSAUGA, ON, March 11, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and fiscal 2024 after the market close on Tuesday, March 18, 2025. The Company will also hold a conference call on Wednesday, March 19, 2025 at...
© PR Newswire
10 December 2024 11:43PM
Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study
MISSISSAUGA, ON, Dec. 10, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that MOB-015, a product for the treatment of nail fungus, did not meet the primary endpoint in the North American Phase...
© PR Newswire
08 November 2024 12:00AM
Cipher Pharmaceuticals Reports Third Quarter 2024 Results
(All figures are presented in U.S. Dollars) Successfully closed the acquisition of the U.S. based Natroba™ business on July 26, 2024Epuris sales volumes grew 29% compared to Q3 2023, continuing growth trajectory for the fifth consecutive quarterStrong product gross margin from the acquired Natroba products of 85%Added management depth with appoin...
© PR Newswire
04 November 2024 01:00PM
Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call
MISSISSAUGA, ON, Nov. 4, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The Company will also hold a conference call on Friday, November 8, 2024 at 8:30am ET...
© PR Newswire
08 October 2024 01:05PM
Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer
MISSISSAUGA, ON, Oct. 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today the appointment of Hamed Ghanei as Chief Business Officer ("CBO"). Craig Mull, Interim Chief Executive Officer, commented on the appointment: "I am delighted to announce the addition of Dr. Ghanei to Cipher's ex...
© PR Newswire
13 September 2024 07:30PM
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
MISSISSAUGA, ON, Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 stud...
© PR Newswire
13 September 2024 04:34PM
Canadian Investment Regulatory Organization Trade Resumption - CPH
TORONTO, Sept. 13, 2024 /CNW/ - Trading resumes in: Company: Cipher Pharmaceuticals Inc. TSX Symbol: CPH All Issues: No Resumption (ET): 10:12:56 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the...
© PR Newswire
13 September 2024 04:25PM
Canadian Investment Regulatory Organization Trading Halt - CPH
TORONTO, Sept. 13, 2024 /CNW/ - The following issues have been halted by CIRO: Company: Cipher Pharmaceuticals Inc. TSX Symbol: CPH All Issues: No Reason: Single Stock Circuit Breaker Halt Time (ET): 10:07:56 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts a...
© PR Newswire
08 August 2024 11:30PM
Cipher Pharmaceuticals Reports Second Quarter 2024 Results
(All figures are presented in U.S. Dollars) Adjusted EBITDA was $3.1 million in Q2 2024, consistent with Q2 2023Epuris sales volumes grew 13% compared to Q2 2023, continuing its growth trajectory for the fourth consecutive quarterStrong operating cash flows of $6.2 million in Q2 2024Management changes to take effect on August 10, 2024:CFO Bryan J...
© PR Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.